AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Effects: Like other NSAIDs, indoprofen can cause gastrointestinal side effects, including:
Cardiovascular Risks: NSAIDs, including indoprofen, have been associated with an increased risk of cardiovascular events such as heart attack and stroke, particularly when used at high doses or for long periods.
Renal Effects: Indoprofen can have adverse effects on kidney function, including:
Hepatotoxicity: Rare cases of liver damage and liver failure have been reported with NSAID use, including indoprofen. Patients with pre-existing liver conditions may be at increased risk.
Allergic Reactions: Some individuals may experience allergic reactions to indoprofen, ranging from mild skin rash to severe hypersensitivity reactions such as anaphylaxis.
Central Nervous System Effects: Indoprofen may cause central nervous system (CNS) side effects, including dizziness, headache, and drowsiness.
Interaction with Other Medications: Indoprofen may interact with other medications, including blood thinners (anticoagulants), antiplatelet drugs, diuretics, and certain antidepressants, leading to an increased risk of bleeding or other adverse effects.
Pregnancy and Lactation: The use of NSAIDs, including indoprofen, is generally not recommended during pregnancy, especially in the third trimester, due to the potential risk of fetal harm. NSAIDs can also pass into breast milk and may affect the nursing infant.
Risk of GI Bleeding and Ulcers: Indoprofen, like other NSAIDs, can increase the risk of gastrointestinal bleeding and ulcer formation, particularly in older adults or those with a history of gastrointestinal disorders.
Other Adverse Effects: Additional adverse effects associated with indoprofen use may include fluid retention, elevated blood pressure, and exacerbation of asthma in susceptible individuals.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 1.1 | 1.1 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergies | 0.3 | 0.3 | 0 |
Alzheimer's disease | 0.3 | 1.3 | -3.33 |
Ankylosing spondylitis | 0.3 | -0.3 | |
Anorexia Nervosa | 0.8 | -0.8 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Asthma | 0.8 | 0.5 | 0.6 |
Atherosclerosis | 0.3 | 0.8 | -1.67 |
Atrial fibrillation | 0.3 | 0.2 | 0.5 |
Autism | 0.8 | 1 | -0.25 |
Autoimmune Disease | 0.5 | -0.5 | |
Barrett esophagus cancer | 0.3 | 0.3 | |
Biofilm | 0 | 0 | |
Bipolar Disorder | 0.5 | -0.5 | |
Brain Trauma | 0.5 | -0.5 | |
Breast Cancer | 0 | 0 | |
Cancer (General) | 0.3 | 0.3 | |
Carcinoma | 0.3 | 0.3 | |
Celiac Disease | 0.3 | 0.3 | |
Cerebral Palsy | 0.5 | -0.5 | |
Chronic Fatigue Syndrome | 0.3 | 0.2 | 0.5 |
Chronic Kidney Disease | 0.7 | -0.7 | |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
Cognitive Function | 0.5 | -0.5 | |
Colorectal Cancer | 0.9 | 0.8 | 0.13 |
Constipation | 0.5 | -0.5 | |
Coronary artery disease | 0.3 | 0.7 | -1.33 |
COVID-19 | 0.9 | 1.9 | -1.11 |
Crohn's Disease | 0.9 | 1 | -0.11 |
cystic fibrosis | 0.5 | -0.5 | |
deep vein thrombosis | 0 | 0.5 | 0 |
Denture Wearers Oral Shifts | 0 | 0 | |
Depression | 0.9 | 1.3 | -0.44 |
Eczema | 0.3 | 0.3 | |
Endometriosis | 0.5 | -0.5 | |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 0.3 | 0.3 | |
erectile dysfunction | 0.3 | 0.3 | |
Fibromyalgia | 1.1 | 1.1 | |
Functional constipation / chronic idiopathic constipation | 0.3 | 0.5 | -0.67 |
gallstone disease (gsd) | 0.8 | -0.8 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 0.3 | 0.3 | |
Graves' disease | 0.5 | -0.5 | |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 0.8 | 0.8 | |
Heart Failure | 0 | 0.7 | 0 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
High Histamine/low DAO | 0.5 | 0.5 | |
hypertension (High Blood Pressure | 0.5 | -0.5 | |
IgA nephropathy (IgAN) | 0.3 | 0.5 | -0.67 |
Inflammatory Bowel Disease | 0.9 | 1.6 | -0.78 |
Insomnia | 0.8 | -0.8 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 0.6 | 0.5 | 0.2 |
ischemic stroke | 0.8 | -0.8 | |
Liver Cirrhosis | 1.1 | 0.8 | 0.38 |
Long COVID | 1.2 | 1.1 | 0.09 |
Low bone mineral density | 0.5 | -0.5 | |
Mast Cell Issues / mastitis | 0 | 0 | |
Menopause | 0.5 | -0.5 | |
Metabolic Syndrome | 0.8 | 0.8 | 0 |
Mood Disorders | 0.8 | 1 | -0.25 |
Multiple Sclerosis | 0.3 | 0.7 | -1.33 |
myasthenia gravis | 0.5 | -0.5 | |
neuropathic pain | 0.5 | -0.5 | |
Neuropathy (all types) | 0.5 | -0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 0.7 | 1 |
Obesity | 0.8 | 0.9 | -0.13 |
obsessive-compulsive disorder | 0.3 | -0.3 | |
Osteoarthritis | 0.6 | 0.6 | |
Osteoporosis | 0.5 | 0.5 | |
pancreatic cancer | 0 | 0 | |
Parkinson's Disease | 0.5 | 2.2 | -3.4 |
Polycystic ovary syndrome | 0.8 | 0.5 | 0.6 |
primary biliary cholangitis | 0.3 | -0.3 | |
Primary sclerosing cholangitis | 0.3 | 0.3 | |
Psoriasis | 0.7 | -0.7 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 1 | -0.67 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 0.3 | 0.5 | -0.67 |
Sjögren syndrome | 0.3 | -0.3 | |
Sleep Apnea | 0.3 | 0.5 | -0.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.8 | 0.5 | 0.6 |
Systemic Lupus Erythematosus | 0.3 | 0.5 | -0.67 |
Type 1 Diabetes | 0.5 | -0.5 | |
Type 2 Diabetes | 1.1 | 0.8 | 0.38 |
Ulcerative colitis | 0.6 | 0.5 | 0.2 |
Unhealthy Ageing | 0.3 | 0.7 | -1.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]